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SUMMARY
The potential of a microparticulate vaccine delivery system in 
eliciting a specific humoral response in the upper respiratory tract of
calves was evaluated. Microparticles composed of poly(lactide-
co-glycolide) containing ovalbumin, a model immunogen, were 
prepared by a solvent evaporation technique. The  microparticles
were under 10µm in diameter as determined by fluorescence 
activated cell sorter (FACS) analysis.
Following immunisation, the microparticles induced production of
specific secretory IgA (sIgA) in nasal samples.The sIgA was detected
after only one week and persisted throughout the length of the study.
Additionally, the effects of microencapsulated synthetic peptides 
(F peptide (0.5mg) and G peptide (0.5mg), representing known 
protective epitopes against bovine respiratory syncytial virus (BRSV),
on the cellular and humoral immune responses of calves were
investigated.
∗ No significant change in the cellular immune response was 
detected.
*  The secretory IgA response was significantly more prolonged 
following administration of the SF  (F111-148) peptide when 
compared with the SG (G174-187) peptide.
*  It is concluded that microparticles incorporating antigens show 
potential in the quest for generating complete protection in the
young bovine against respiratory tract pathogens.
*  Vaccination of calves with the SF (F111-148)  and  SG (G174-187)
peptide resulted in a significant reduction in the requirement to treat with
antibiotics for respiratory disease in the post-vaccination period.
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INTRODUCTION
Respiratory disease in calves and growing cattle has long been 
recognised as a major problem for the cattle industry throughout the
world.The underlying cause of bovine respiratory disease is 
extremely complex with the involvement of viruses and bacteria.The 
incidence of infection (morbidity) is usually high, but the mortality
rate is variable.Viruses that have been predominantly isolated from
outbreaks of calf pneumonia are infective bovine rhinotracheitis
(IBR), respiratory syncytial virus (RSV), parainfluenza-3 virus (PI-3
virus), and bovine virus diarrhoea/mucosal disease (BVD/MD virus).
Predisposing factors affecting immunocompetence (ability to fight
infection) are stress, overcrowding, inadequate ventilation, draughts,
fluctuating temperatures, poor nutrition and/or concurrent disease.
In most cases it would appear that the primary infective agent is viral,
producing respiratory tract damage that is subsequently extended by
Mycoplasmas and secondary bacterial infections. In an Irish survey
(Healy et al., 1993) in a slatted unit containing 6399 beef cattle over
a six month period respiratory disease was the most frequently
recorded case of morbidity and mortality, and this observation is in
agreement with reports from large feedlots in America (Jensen et al.,
1976). In a Northern Ireland bovine mortality study, involving 38% of
the total cattle population, respiratory disease was the most 
common cause of mortality in animals from 1 to 24 months of 
age, with pneumonia of unknown aetiology being the most common 
syndrome associated with it  (Reul, 1977).
Estimates of economic losses vary but are considered to be 
substantial as demonstrated by a study in Scotland, in which, the loss
incurred was calculated at £21 per animal at risk for 152 outbreaks.
For the most severe outbreak the cost was estimated at £114 per
calf at risk (Gunn, 1998).The prevalent respiratory disease condition
in housed calves is enzootic pneumonia or sudden-onset acute
pneumonia.The importance of sound animal management cannot be 
overlooked and factors such as adequate colostrum intake in early
life, prevention of co-mingling of different age groups and avoidance
4
5867 BIO TEXT (4626).34  29/1/02  2:38 pm  Page 4
of stressful procedures.(e.g. weaning, castration, dehorning) during
high risk periods for disease cannot be overemphasised. Most
pathogens enter the host via a mucosal surface and so one of the
best ways to protect against infection would be to stimulate strong
specific immunity at these mucosal sites. Most vaccines are adminis-
tered systemically and so, whilst generating strong systemic immune
responses, in general they stimulate only poor mucosal immunity. In
the last ten years or so, attention has focused on methods of deliv-
ery of vaccines which stimulate strong mucosal immunity, and poly-
meric microparticles composed of poly DL-lactide-co-glycolide have
been widely studied particularly in rodents (O'Hagan et al., 1989;Yan,
et al., 1996; Challacombe et al., 1997;Alpar et al., 1998).There is evi-
dence that uptake of orally-administered particulate systems is by the
microfold (M) cells of the gut- associated lymphoid tissue (GALT)
(Eldridge et al., 1990) and it has been suggested that uptake of par-
ticulates by the nasal route is effected by a similar process involving
nasal associated ymphoid tissue (Alpar et al., 1994; Heritage et al.,
1998). Mucosal application of an antigen can lead to induction of
both systemic and mucosal immune responses (Maloy et al., 1994;
Eyles et al., 1998) and the use of polymeric particulate systems to
deliver antigens to respiratory mucosae could provide a useful sys-
tem for vaccination of the respiratory tract.
Non-live sub-unit vaccines encapsulated in biodegradable microparti-
cles is a novel approach to achieving a protective immune response
against specific pathogens in the host's respiratory tract. The main
objective of the present study was to investigate the potential of
microparticles composed of poly(lactide-co-glycolide) containing a
model antigen, ovalbumin (OVA) in calves. Long experience with this
polymer has shown that it is completely biodegradable and non-
toxic. The immunogenicity of the microspheres administered
intranasally is demonstrated by the presence of an ovalbumin-specif-
ic humoral immune response in the upper respiratory tract of the
inoculated animal. The appropriate dose of encapsulated OVA was
also optimised. Chicken egg albumin (ovalbumin) was chosen as the
subunit protein for preliminary work because it is a well charac-
5
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terised model immunogen (Nakaoka et al., 1995; Rafati et al., 1997)
and is foreign to the animal species used in this project.
Vaccines
Classical vaccines generally consist of either whole inactivated or live
attenuated micro-organisms, which are often sufficiently immuno-
genic to induce potent immune responses without theaddition of an
adjuvant. However advances in biotechnology and chemical synthe-
sis have resulted in new approaches to vaccine development involv-
ing the synthesis of protein or peptide sequences that are homolo-
gous with epitopes capable of inducing protective immunity against
infectious organisms. This newer approach can be termed the sub-
unit' approach. Subunit vaccines prepared by chemical synthesis or
biotechnology have several advantages over traditional vaccines; they
are chemically well defined, can be reproducibly prepared and readi-
ly assayed and are inexpensive to manufacture. However a general
drawback is poor immunogenicity resulting in the need for multiple
administrations thus few effective subunit vaccines have been pro-
duced to date.
Encapsulation of subunit antigens into polymeric microparticles may
overcome some of the problems with this approach. The polymer
particles can be either monolithic with the antigen interspersed
throughout the matrix, or consist of true capsule wall structures with
a core antigen load within (reservoir microcapsules). The size of 
particles can range from 300µm to less than 1µm depending on the
manufacturing procedure.
The polymer of choice for vaccine delivery is poly DL lactide-co-gly-
colide (PLG) a biocompatible and biodegradable compound. This
copolymer consists of lactic acid and glycolic acid, both by-products
of normal mammalian energy metabolism. Polylactide-co-glycolide
formation results in compounds of approximately 40kDa in 
molecular weight and degrades over time by random, non-enzymatic
hydrolysis. The rate of biodegradability is influenced by several
physicochemical factors so controlled release of antigen may be
achieved at pre-determined timepoints to maximise the immune
6
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response generated.
Materials and Methods
Microparticle Preparation 
Microparticles containing ovalbumin (OVA) were prepared using a
poly(lactide-co-glycolide) polymer with a molecular weight of 40-75
kDa and a lactide/glycolide ratio of 50:50. The microspheres were
prepared by a solvent evaporation technique from an water-oil-in-
water (w/o/w) emulsion as described by o'Hagan. Briefly, 1ml of OVA
in double-distilled water (60mg/ml) was mixed with 5ml of 60mg/ml
polymer dissolved in dichloromethane using a Silverson 
homogeniser.This emulsion was then homogenised into 10ml of the
emulsion stabiliser, polyvinyl alcohol (PVA)(50mg/ml double-distilled
water) to form the final stable w/o/w solution. The emulsion was
stirred overnight at room temperature to allow the evaporation of
the solvent and resultant microsphere hardening. Microparticles
were washed three times in 0.1% PVA, collected by centrifugation,
freeze dried and stored at -20ºC.
Scanning Electron Micrograph of microparticles
Microsphere Characterisation
The content of encapsulated ovalbumin was determined using a
bicinchoninic acid (BCA) protein determination assay after 
dissolution of approximately 10mg of microparticles in 600µl 0.1M
NaOH containing 5% sodium dodecyl sulphate. The extraction was
7
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stopped after 4 hours at 37°C in an orbital shaker with 500µl 0.1M
HCl, the solution was centrifuged and the supernatant removed for
analysis. The surface morphology and mean size of the microparti-
cles was determined by scanning electron microscopy. Variations in
particle size distribution was observed by flow cytometry using 5µm
and 10µm fluorescent beads as size markers.
In vitro protein release kinetics
Duplicate samples of the microsphere preparation (approximately
20mg) were suspended in 2ml sterile PBS (pH 7.2) in 2ml glass 
universals. The solution was agitated continuously at 200rpm in an
orbital shaker at 37°C. After 24hr, 48hr, 72hr and weekly thereafter
the samples were centrifuged at 3000rpm for 5 minutes and 1.9ml of
the supernatant was removed and replaced by resuspension in fresh
sterile PBS.The supernatant was analysed for protein content using
the BCA protein assay.The release studies were continued over a 10
week period.
Micro-Bicinchoninic acid  protein assay
Bicinchoninic acid (BCA) working reagent was prepared by 
combining 50 parts of BCA stock solution and 1 part of 4%
CuSO4.5H2O. A set of ovalbumin standards in PBS was prepared
using sterile PBS for the in vitro release study (1000mg/ml-
3.125mg/ml) and a 1:1 ratio of 0.1M HCl:0.1M NaOH containing 5%
SDS for the evaluation of total protein content (2000mg/ml-
25mg/ml). 10ml of each standard, unknown sample and blank was
added to a 96-well Nunc plate and 200ml of working BCA solution
was added.The microtitre plate was covered with a lid and incubat-
ed for 20 minutes at 37°C with gentle shaking.Absorbance of water-
soluble purple product was measured at 570nm using a microplate
reader.
8
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Immunisation protocol (1)
Holstein/Friesian calves (approximately 8 months old) were 
randomly divided into 3 groups of 4 and administered either (1)
0.5mg, (2) 1.0mg, or (3) 5.0mg of encapsulated OVA. Microspheres
were suspended in 2ml sterile PBS immediately before immunisation
and administered using an intranasal applicator attached to a 5ml
syringe.The animal's heads were held upright for 30 seconds to pre-
vent rejection of the inoculum. All animals received the appropriate
booster dose of encapsulated OVA intranasally 5 weeks after the pri-
mary inoculation.
Collection of Biological Fluids
Pre-immune sera and nasal mucous samples were collected the
morning before primary immunisation and weekly thereafter for 10
weeks. Blood samples were collected by jugular venipuncture and
left overnight at 37°C to separate the serum from plasma.The serum
was obtained by centrifugation at 3000RPM for 5 minutes and stored 
at -20°C. Nasal mucosa washings were collected by inserting a
sponge into the animals' nostril for 10 minutes.Nasal secretions were
centrifuged at 3000 RPM for 5 minutes at 4°C to remove aggregated
mucus and stored at -20°C.
Antibody Detection.
The presence of OVA-specific IgA and IgG antibody content in  nasal
washings and sera respectively, was detected using an ELISA 
procedure. Briefly, ninety-six-well ELISA plates (Dynatech) were coat-
ed overnight with 10µg/ml OVA in 0.05 M sodium carbonate-bicar-
bonate buffer (pH 9.6) at 4°C. Plates were washed thoroughly with
PBS containing 0.05% Tween 20 (PBS-T). Nasal wash samples and sera
samples were diluted 1/10 and 1/20 respectively, in 5% nonfat dried
milk (Marvel) in PBS-T and incubated for 1 hour at 37°C. Plates were
washed thoroughly and mouse anti-bovine IgA or rabbit anti-bovine
IgG horse radish peroxidase conjugate at a dilution of 1/100 and
1/20,000 respectively in PBS-T was added to the wells for 1 hour at
37°C. Plates were washed and goat anti-mouse IgG horse radish per-
9
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oxidase conjugate diluted 1/500 in PBS-T was added to the nasal IgA
plates for 1 hour at 37°C. The plates were washed and 3,3'5,5'-
tetramethlbenzidine (TMB) substrate was added to each well and the
colorigenic reaction was stopped after 5 minutes at ambient tem-
perature with 0.1M HCl.Absorbance values were read at 450 nm by
an ELISA reader.The results for the IgA assay were expressed as anti-
body units calculated from a standard curve of a pooled nasal wash
sample diluted between 1/2 and 1/32. Furthermore, to allow for dif-
ferences in nasal wash protein content, these results were normalised
to total protein concentration for each sample, as determined by the
BCA assay. For the IgG ELISA, themean absorbance values were stan-
dardised using sera from a calfhyperimmunised to OVA.
Immunization protocol (2)
Seventy-eight mart purchased Holstein/Friesian calves were 
approximately 18 days of age on arrival at the research centre.The
calves were allocated randomly and received one of the following 6 
treatments (13 per treatment); 1). Soluble F-peptide (SF) and soluble
G-peptide (SG) in phosphate buffer saline (PBS); 2).
Microencapsulated Ppoly(lactide-co-glycolide (PLG)-peptide-F and
PLG-peptide-G); 3).Microencapsulated coupled to hexapeptiide (PLG
Hexa-peptide-G and PLG hexa-peptide-F); 4). Microencapsulated
coupled to ovalbumin (OVA) (PLG OVA-peptide-G and PLG 
OVA-peptide-F); 5). Ovalalbumin + 20mg microencapsulated cholera
toxin 6). Phosphate buffered saline control. The sequence of the
BRSV fusion protein from the RB94 (Rispoval vaccine) representing
the amino acid region was 111-PELIHYTRNSTKRFYGLMGKKRKR-
RFLGFLLG IGSAI-148 (F111-148) (SF). The amino acid sequence
174-STCEGNLACLSLSK-187 with a Cys-Ser substitution at position
184 (G174-187) (SG) represents the corresponding region of the
attachment protein of the BRSV strains. Free or conjugated peptide
was encapsulated in microparticles consisting of poly(lactide-co-gly-
colide) polymer with a molecular weight of 40-75kDa and a 
lactide/glycolide ratio of 50/50 (Sigma-Aldrich Co. Ltd, Poole, UK).
There is preliminary evidence that the G protein is incorporated into
the envelope of the BHV-1 virions and it may, therefore, facilitate
10
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virus attachment and replication in the lower respiratory tract.
On day 38 after arrival and immediately before nasal administration
the freeze-dried microspheres containing the encapsulated peptides
(F and G) were suspended in 2ml of sterile physiological PBS and
administered to individual calves in a syringe fitted with an intranasal
applicator. Nasal mucosa washings were collected on the day of 
inoculation and on days 28 and 77 post-primary inoculation for the
determination of secretory IgA antibody levels in response to inocu-
lation. Gamma interferon production in response to concanavalin-A
(Con-A)  was determined in cultured lymphocytes on days 28 and
142 post-primary inoculation. Ten ml of blood wascollected into
evacuated blood collecting tubes containing heparin (Vacutainer
Systems, Becton Dickinson Systems Europe, Meylan Cedex, France)
at predetermined timepoints. A commercially available sandwich
ELISA kit (Bovigamä, CSL Veterinary Ltd.,Victoria,Australia) was used
for the quantification of bovine interferon-γ in blood samples. Serum
immunoglobulins (IgG1) were measured 
Laminar flow unit for cell culture procedures
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quantitatively by single radial immunodiffusion on day 28 post-inocu-
lation.The calves had ad libitum access to a concentrate ration and
roughage (straw) throughout the experimental period. Clean fresh
water was available at all times. Individual disease episodes were
determined by the requirement to treat for either enteric disease or  
respiratory disease.The data were analysed using analysis of variance
procedure and if a significant difference was observed, Duncan's 
multiple range test  was applied to determine statistical differences
between treatments.
Haematological variable
Calves were blood sampled by jugular venipuncture on arrival (and
on days 35 and 140 after arrival at Grange Research Centre. The
physiological parameters measured were: red blood cell number
(RBC), haemoglobin (Hb), packed cell volume (PCV), mean cell vol-
ume (MCV), total white cell (TWC) count, platelet number, % 
lymphocytes, blood copper (Cu2+), glutathione peroxidase (GPX).
Haematology parameters were determined for unclotted (K3-EDTA)
whole blood samples using an electronic particle analyser (Celltac
MEK-610K). (Tables 2 - 7) (Appendix 1). Specific changes in haema-
tological parameters are referenced to in the Tables (2-7).
Immunoglobulin determination
Serum immunoglobulins (IgG1) were measured quantitatively by sin-
gle radial immunodiffusion (sRID) (Mancini et al., 1965) andcalculated
via an internal Ig standard (BINDARID, NANORID kits.The Binding
site Ltd., R&D, Birmingham, UK.). The zinc sulphate turbidity (ZST)
test was performed on all serum samples at 20oC with turbidity
readings carried out at 520nm using a spectrophotometer (McEwan
et al., 1970).
12
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Results and discussion
In this series of experiments we set out to determine the suitability
of a novel micro particulate vaccine delivery system to elicit a mucos-
al antigen-specific immune response in the upper respiratory tract of
young calves. In all inoculated calves significant levels of ovalbumin-
specific secretory IgA was detected as early as one week post-admin-
istration and levels persisted throughout the duration of the study
(Figures 1 and 2). Peak levels of IgA were detected in all calves at
week 3.The lowest dose of encapsulated antigen elicited the greatest
Figure.1 Immunogenicity of different doses of OVA encapsulated
in poly(lactide-co-glycolide)(PLG-OVA): Detection of
ovalbumin-specific IgA in nasal mucosa washes 
8-month old calves.
Figure 2. Detection of specific IgG in calf sera intranasally 
inoculated with either 0.5mg, 1.0mg or 5.0mg of
microencapsulated ovalbumin.
5867 BIO TEXT (4626).34  29/1/02  2:38 pm  Page 13
immune response. Conversely this same dose resulted in the weak-
est systemic humoral response.The baseline Ig antibody response to
maternal RSV antigens are presented for all 
treatments at 5, 8 and 10 weeks of age in Table 1. It was important to 
quantify the RSV antibody titers in calves prior to vaccination in
order to rule out any possible neutralization of the novel vaccine
when intra-nasally administered to calves.The titres wre significantly
lower at 10 weeks of age when values were compared with the data
obtained at 5 weeks of age. There was no difference (P>0.05)
between treatments in response to concanavalin-A (Con-A) induced
interferon (IFN) and production from lymphocytes cultured on days
28 or 142 indicating that the vaccination had no effect on the cellu-
lar immune response (Table 2). There was no significant difference in
serum Ig concentrations (Table 3) or ZST units across treatments
(P>0.05) (Table 4) indicating that there was no changes in the Ig 
status of calves throughout the experimental period.
The results presented in Table 5 and Table 6 demonstrated that
intranasal administration of ovalbumin in biodegradable 
poly(lactide-co-glycolide) particles less than 10µm in diameter 
generated an antigen-specific systemic and mucosal antibody
response in calves. A sustained  antigen-specific IgA response was
induced in the calves nasal mucosa and lungs by all treatments
(P < 0.05) when compared with PBS control calves on day 28. On
Day 77 post-primary inoculation the antigen-specific IgA response to
the F peptide subunit was significantly higher (Table 5) and more 
sustained compared with the response of the G peptide subunit 
(P< 0.01) (Table 6). Haematological parameters were determined
using an electronic particle analyser (Nihon Kohdon). On day 35,
prior to vaccination, all calves were blood sampled. The total white
blood cell counts were significantly higher (P < 0.05) in the SF+SG
treatment (11.35 ± 0.90) and PLG-F+PLG-G treatment (11.02 ±
1.10) versus PLG OVA-F+PLG OVA-G treatment (8.33 ± 0.39).
Similarly, calves in the PBS control group had significantly lower white
blood cell counts (8.63 ± 0.49) than calves in the SF+SG treatment
(11.35 ± 0.90) and PLG-F+PLG-F treatment (11.02 ± 1.10).
14
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By 140 days after arrival at Grange, the total white blood cell counts
were significantly higher (P < 0.05) in the SF+SG treatment (13.35 ±
0.63) and PLG-F+PLG-G treatment (13.52 ± 0.79) compared with
the PBS control (10.75 ± 1.97).The total white cell counts were sig-
nificantly higher (P<0.05)in the PLG-F+PLG-G treatment (13.52 ±
0.79) compared with the PBS control treatment (10.75 ± 1.97) and
PLG-OVA G+PLG-OVA F treatment (11.33 ± 0.65). The incidences
of respiratory disease prior to (Table 7a) and in the period after 
vaccination were recorded in calves. Following vaccination there was
a significant reduction in the requirement to treat calves with 
antibiotics for respiratory disease (Table 7b). Non-vaccinated calves
had  significantly higher  incidences of respiratory disease compared
with calves that had been treated with different formulations of the
soluble F and soluble G peptides.There was no significant difference
in incidences of enteric disease across treatments (Table 7c).
Liveweight gain from day 0 to day 140 of the study (Table 8) was not
affected (P > 0.05) by vaccine administration.
Immunisation Protocol (3)
18 Calves (Holstein x Fresian) were randomly assigned to 
treatments. All animals were intranasally inoculated with the
microparticle preparation containing 1mg of protein antigen. Nasal
mucosal wash samples were collected to measure the levels of anti-
gen-specific IgA in the bovine upper respiratory tract. Samples were
collected fortnightly for 16 weeks and monthly thereafter.
Antibody Detection
The presence of OVA-specific IgA antibody content in nasal washings
was detected using an ELISA developed by the authors. The results
for the assay were recorded as a fraction of a positive control and
normalised to the total protein concentration expressed as IgA
antibody units.
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Results
Following intranasal (in) inoculation the microparticles generated a
persistent antigen-specific immune response in the nasal washings
which lasted for the duration of the 4 month study (Figure 3 and 4).
Furthermore, nasal antigen-specific IgA levels for animals not given a
secondary booster immunisation were equivalent to those animals
which were boosted due to the controlled release of antigen 
(Figure 4).
It is concluded that intranasally administered antigen encapsulated in
biodegradable microparticles generates specific immunity at the site
of pathogen infection in the upper respiratory tract of calves and the
young bovine.The persistence of antigen-specific IgA antibody in the
nasal washings of immunised animals is a very encouraging feature of
16
Figure 3. Persistence of antigen-specific immunity in the bovine 
upper respiratory tract: Measurement of ovalbumin
-specific IgA levels in nasal washings of 5 week old calves 
intranasally administered 1mg of microencapsulated antgen.
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this novel vaccine delivery system and may generate long lasting
levels of local anti-viral protection. Furthermore, nasal OVA-specific
IgA levels for animals not given a secondary booster immunisation
were equivalent to those of animals which were boosted due to the
sustained release of antigen from particles over time. These results
suggest this novel vaccine delivery system may not only be more
effective in neutralising pathogens which reside in the respiratory
tract but may also be effective as economical single shot vaccines. It
is concluded that this protein delivery system may possess several
advantages over conventional methods of respiratory tract vaccina-
tion in large animals.
With most of the viruses involved in severe respiratory disease in
calves the immune response is complicated, and particularly with RSV
there is substantial evidence that the immune response to certain
viral proteins contributes to the severity of the ensuing disease.
Most of the viruses involved are also immunosuppressive and can
adversely affect the normal function of macrophages and lympho-
cytes (Adair and McNulty 1992;Adair et al., 1992a,b). Conventional
respiratory virus vaccines largely comprise whole virus preparations
administered live or as killed preparations. Fieldexperience tends to
17
Figure 4. Efficacy of a single shot vaccine delivery system in the young
bovine: Measurement of ovalbumin-specific IgA levels in nasal
washings generated by intra nasal  (I.N.) administration of one
or two 1mg doses of encapsulated antigen.
no booster (n=6)
week 3 (n=6)
Negative threshold (n=12)
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suggest that efficacy declines rapidly with time following vaccination.
Current approaches to vaccine development are therefore aimed at
improving vaccine performance by eliminating the protein compo-
nents of pathogens which contribute to adverse reactions or
immunosuppression, while retaining immunogenicity. This can only be
achieved by improved understanding of immune responses, particu-
larly cellular events, and how protective immunity can be stimulated
over long periods at mucosal surfaces where 
infection is initiated.
CONCLUSIONS
*  No significant change in the cellular immune response was 
detected. It is concluded that at eleven weeks post-inoculation, the
IgA response was significantly more prolonged following administra-
tion of the SF (F111-148) peptide when compared with the 
SG (G174-187) pep tide.
*  It is concluded that microparticles incorporating antigens 
show potential in the quest for generating complete protection in the
young bovine against respiratory tract pathogens.
*  Vaccination of calves with the SF (F111-148)  and SG (G174-187)
peptide resulted in a significant reduction in the requirement to treat
with antibiotics for respiratory disease in the post-vaccination period.
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Table 1. RSV antibody titers in  calves. The values are expressed as Mean ± s.e.m.
Age of SF+SG PLG-F + PLG Hexa PLG Ova Ova + PBS
calves FPLG-G G + G + 20 mg Control
PLG Hexa PLG Ova Cholera
F F Toxin
5 weeks 0.84 0.74 0.7 2 0.74 0.61 0.79
± 0.054 ± 0.049 ± 0.077 ± 0.053 ± 0.070 ± 0.059
8 weeks 0.74 0.67 0.68 0.69 0.59 0.69
± 0.035 ± 0.052 ± 0.229 ± 0.061 ± 0.057 ± 0.050
10 weeks 0.55 0.46 0.54 0.49 0.46 0.52
± 0.043 ± 0.069 ± 0.061 ± 0.055 ± 0.059 ± 0.056
Calf serum RSV antibody levels in response to maternal levels.
Table 2. Plasma interferon gamma levels in control and vaccinated calves on days 
28 and 142 post-vaccination.The values are expressed as Mean  levels 
(OD at 450 nm) ± s.e.m.
SF+SG PLG-F + PLG Hexa PLG Ova Ova + PBS
PLG-G G + G + 20 mg Control
PLG Hexa PLG Ova Cholera
F F Toxin
Microencapsulated
Gamma interferon  in response to Con-A stimulation. Mean OD ± sem units at 450nm
Day 28 0.95 1.05 0.88 1.11 0.73 0.68
± 0.181 ± 0.297 ± 0.194 ± 0.182 ± 0.111 ± 0.083
Day 142 0.67 0.79 0.57 0.58 0.53 0.65
± 0.117 ± 0.198 ± 0.161 ± 0.137 ± 0.122 0.127
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Table 3: Serum IgG1 concentrations in control and vaccinated calves on 
arrival and at 21, 42 and 63 days post-arrival at Grange Research 
Centre.
Groups Serum IgG11 concentrations
Day 0 Week 3 Week 6 Week 9
SF+SG 20.07 ± 20.24 ± 25.05 ± 21.56 ±
3.05 2.95 1.65 1.64
PLG-F + 22.87 ± 22.55 ± 23.82 ± 20.35 ±
PLG-G 3.99 3.00 2.42 1.03
PLG Hexa G + 22.81 ± 18.35 ± 22.77 ± 21.19 ±
PLG Hexa F 4.16 1.93 1.33 1.13
PLG Ova G + 25.03 ± 22.31 ± 23.38 ± 20.43 ±
PLG Ova F 3.39 2.13 2.008 1.28
Ova + 20.66 ± 25.08 ± 25.37 ± 24.28 ±
20 mg CT 2.04 2.82 2.24 1.99
PBS 20.81 ± 20.71 ± 23.64 ± 21.83 ±
Control 3.29 2.50 2.60 1.53
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Table 4 : ZST Units in control and vaccinated calves.The values are expressed as
mean Units ± sem.
Groups Day 0 Day 7 Day 14 Day 21 Day 28
SF+SG 9.56 ± 11.27 ± 14.20 ± 10.45 ± 13.40 ±
1.35 0.975 1.05 0.57 0.53
PLG-F + 9.57 ± 11.37 ± 13.87 ± 10.76 ± 13.30 ±
PLG-G 1.45 1.45 1.24 1.01 0.77
PLG Hexa G + 8.54 ± 9.94 ± 13.64 ± 10.47 ± 13.47 ±
PLG Hexa F 0.77 0.86 0.81 0.51 0.69
PLG Ova G + 10.94 ± 11.66 ± 13.88 ± 10.82 ± 13.48 ±
PLG Ova 0.96 0.70 0.78 0.57 0.50
Ova + 10.58 ± 11.41 ± 13.88 ± 10.84 ± 14.02 ±
20 mg CT 1.03 1.06 0.88 0.55 0.49
PBS 8.66 ± 10.71 ± 14.01 ± 10.24 ± 13.33 ±
Control 0.99 0.90 0.93 0.76 0.62
Day 35 Day 42 Day 49 Day 56 Day 63
SF+SG 11.59 ± 10.58 ± 11.12 ± 13.01 ± 16.47 ±
0.49 0.52 0.57 0.96 1.54
PLG-F + 11.40 ± 10.27 ± 10.96 ± 12.21 ± 18.02 ±
PLG-G 0.54 0.63 0.48 1.08 1.44
PLG Hexa G + 11.96 ± 10.70 ± 10.70 ± 12.55 ± 18.22 ±
PLG Hexa F 0.43 0.58 0.70 0.85 1.76
PLG Ova G + 11.03 ± 9.86 ± 10.84 ± 11.62 ± 17.78 ±
PLG Ova F 0.56 0.28 0.53 0.73 1.33
Ova + 12.02 ± 11.13 ± 11.97 ± 13.92 ± 18.48 ±
20 mg CT 0.42 0.68 0.73 0.99 1.36
PBS 11.20 ± 10.67 ± 11.76 ± 13.46 ± 20.22 ±
Control 0.54 0.78 0.77 1.03 1.60
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Table 5. Secretory IgA concentrations in response to F peptide microencapsulation 
in control and vaccinated calves.The values are expressed as Mean ± s.e.m.
SF+SG PLG-F + PLG Hexa PLG Ova Ova + PBS
FPLG-G G + G + 20 mg Control
PLG Hexa PLG Ova Cholera
F F Toxin
Microencapsulated
G peptide IgA response
Day 0 0.007 0.007 0.006 0.008 0.006 0.008
± 0.001 ± 0.001 ± 0.001 ± 0.001 ± 0.001 ± 0.002
Day 28 0.022a 0.021a 0.017 a 0.020 a 0.019 a 0.008b
± 0.002 ± 0.002 ± 0.002 ± 0.003 ± 0.004 ± 0.002
Day 77 0.012  0.011 0.013 0.012 0.011 0.007 
± 0.002 ± 0.002 ± 0.002 ± 0.002 ±0.001 ± 0.002
a,b, means without a common superscript differ  (P< 0.05)
Table 6: Secretory IgA concentrations in response to G peptide microencapsulation 
in control and vaccinated calves.The values are expressed as Mean ± s.e.m.
SF+SG PLG-F + PLG Hexa PLG Ova Ova + PBS
FPLG-G G + G + 20 mg Control
PLG Hexa PLG Ova Cholera
F F Toxin
Microencapsulated
F peptide IgA response 
Day 0 0.023 0.020 0.016 0.020 0.016 0.020
± 0.003 ± 0.002 ± 0.001 ± 0.002 ± 0.001 ± 0.001
Day 28 0.049 a 0.056 a 0.045 a 0.052 a 0.044 a 0.019 b
± 0.004 ± 0.007 ± 0.005 ± 0.067 ± 0.009 ± 0.002
Day 77 0.037 a 0.037 a 0.035 a 0.034 a 0.034 a 0.016 b
± 0.003 ± 0.005 ± 0.003 ± 0.004 ± 0.004 ± 0.002
a,b, means without a common superscript differ  (P< 0.05)
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Table 7b. Incidences of pneumonia  in control and vaccinated calves.
SF+SG PLG-F + PLG Hexa PLG Ova Ova + PBS
FPLG-G G + G + 20 mg Control
PLG Hexa PLG Ova Cholera
F F Toxin
Treatment Pneumonia
0 9 10 11 11 11 7
1 3 3 1 2 1 4
2 1 - 1 - - 2
3 - - - - 1 -
4 or more - - - - - -
Significance P = 0.022 P = 0.026 P = 0.001 P = 0.011 P = 0.012 P = 0.198
of post ns
versuspre 
treatment 
Mann-Whitney U test  - incidences of calf pneumonia prior to and post vaccine administration.
NS = non significant
Table 7a. Incidences of pneumonia in calves prior to vaccination
SF+SG PLG-F + PLG Hexa PLG Ova Ova + PBS
FPLG-G G + G + 20 mg Control
PLG Hexa PLG Ova Cholera
F F Toxin
Treatment Pneumonia
0 3 5 2 5 4 4
1 7 4 6 4 4 5
2 1 - 3 3 2 3
3 1 3 1 1 2 1
4 or more 1 1 1 - - -
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Table 7c. Incidences of enteric disease in control and vaccinated calves.
Treatment Enteric disease
0 10 12 11 13 13 12
1 2 2 2 0 0 1
2 0 0 0 0 0 0
3 1 0 0 0 0 0
4 or more 0 0 0 0 0 0
Table 8: Liveweight gain (kg/day).
SF+SG PLG-F + PLG Hexa PLG Ova Ova + PBS
FPLG-G G + G + 20 mg Control
PLG Hexa PLG Ova Cholera
F F Toxin
Liveweight gain
(kg/day)
Day 0 -  day 35 0.56 ± 0.55 ± 0.58 ± 0.56 ± 0.52 ± 0.59 ±
0.032 0.036 0.042 0.034 0.055 0.042
Day 35 – day 63 0.99 ± 0.97 ± 1.03 ± 1.01 ± 0.88 ± 0.93 ±
0.044 0.020 0.054 0.039 0.078 0.070
Day 35 – Day 77 1.094 ± 1.052 ± 1.107 ± 1.086 ± 0.98 ± 0.98 ±
0.054 0.032 0.064 0.045 0.080 0.064
Day 35 – Day 140 0.93 ± 0.92 ± 0.94 ± 0.97 ± 0.83 ± 0.85 ±
0.051 0.041 0.045 0.048 0.073 0.053
Animals vaccinated on day 35 after arrival at Grange Research Centre.
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